Scarica l'app Stockscreener
2.365
3.47%
-0.085
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.45
Aprire:
$2.6
Volume 24 ore:
19,844
Relative Volume:
0.42
Capitalizzazione di mercato:
$11.66M
Reddito:
$468.00K
Utile/perdita netta:
$-10.34M
Rapporto P/E:
-0.3355
EPS:
-7.05
Flusso di cassa netto:
$-8.94M
1 W Prestazione:
-4.25%
1M Prestazione:
+1.94%
6M Prestazione:
-17.02%
1 anno Prestazione:
-64.84%
Intervallo 1D:
$2.32
$2.61
Intervallo di 1 settimana:
$2.12
$2.73
Portata 52W:
$1.625
$8.85
Biocardia Inc Stock (BCDA) Company Profile
Nome
Biocardia Inc
Settore
Industria
Telefono
650-226-0123
Indirizzo
320 SOQUEL WAY, SUNNYVALE, CA
Confronta BCDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1978 | 409.20M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.70 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4356 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.26 | 96.03M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.00 | 52.42M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-16 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Borsa (BCDA) Ultime notizie
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
BioCardia (NASDAQ:BCDA) Upgraded at Alliance Global Partners - Defense World
BioCardia upgraded to Buy from Neutral at Alliance Global Partners - Yahoo Finance
BioCardia, Inc. Announces Acceptance of CardiAMP HF Phase 3 Study Results for Presentation at ACC 2025 - Defense World
First Patient Dosed in Phase 1 Trial of GTB-3650On January 27, 2025, GT Biopharma, Inc. (NASDAQ:GTBP) made a significant stride in its clinical development efforts with the announcement that the first patient was dosed in the Phase 1 Trial of GTB-365 - Defense World
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions - The Manila Times
BioCardia to Present CardiAMP Phase 3 Heart Failure Trial Results at ACC 2025 - StockTitan
Comparing Apogee Therapeutics (NASDAQ:APGE) and BioCardia (NASDAQ:BCDA) - Defense World
BioCardia (FRA:6JU0) Cyclically Adjusted FCF per Share : €-23.57 (As of Sep. 2024) - GuruFocus.com
Biocardia senior vice president Edward Gillis sells $6,514 in stock - Investing.com India
Biocardia CEO Peter Altman acquires shares worth $2,060 By Investing.com - Investing.com Australia
Biocardia CEO Peter Altman acquires shares worth $2,060 - Investing.com
BioCardia’s (BCDA) “Buy” Rating Reiterated at HC Wainwright - Defense World
BioCardia stock plunges to 52-week low of $1.81 amid market challenges - Investing.com
BioCardia, Inc. (NASDAQ:BCDA) Sees Significant Decrease in Short Interest - Defense World
BioCardia's SWOT analysis: cell therapy stock faces pivotal trial phase - Investing.com India
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family - The Manila Times
BioCardia, Inc. Announces Commercial Availability of Morph DNA Steerable Introducer Product Family - Marketscreener.com
BioCardia's SWOT analysis: cell therapy stock faces pivotal trial phase By Investing.com - Investing.com Canada
Biocardia CEO Peter Altman buys $555 in common stock By Investing.com - Investing.com Nigeria
Biocardia CEO Peter Altman buys $555 in common stock - Investing.com
Microcatheters Market Surges to USD 1.53 Billion by 2032, Propelled by 5.53% CAGRReport by S&S Insider - GlobeNewswire
BioCardia Reports Successful Consultation with Japan’s PMDA on BCDA-01 RegistrationSunnyvale, California – December 4, 2024 – BioCardia, Inc. (NASDAQ: BCDA) has recently disclosed a significant achievement regarding its lead therapeutic asset, BC - Defense World
BioCardia's SWOT analysis: cell therapy firm's stock faces clinical trial hurdles - Investing.com India
BioCardia nears Japan registration for heart failure therapy By Investing.com - Investing.com Nigeria
BioCardia nears Japan registration for heart failure therapy - Investing.com India
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure - The Manila Times
BioCardia's Heart Failure Treatment Gains Momentum with Promising PMDA Regulatory Path in Japan - StockTitan
Biocardia CEO Peter Altman acquires $2,524 in common stock By Investing.com - Investing.com Nigeria
Biocardia CEO Peter Altman acquires $2,524 in common stock - Investing.com
BioCardia (NASDAQ:BCDA) vs. Osiris Therapeutics (OTCMKTS:OSIR) Head-To-Head Analysis - Defense World
HC Wainwright Increases Earnings Estimates for BioCardia - Defense World
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) - Yahoo Finance
BioCardia stock plunges to 52-week low, touches $1.93 - Investing.com India
BioCardia stock plunges to 52-week low, touches $1.93 By Investing.com - Investing.com Nigeria
BioCardia, Inc. (NASDAQ:BCDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: BioCardia announces progress in heart therapy trials By Investing.com - Investing.com UK
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthro - GuruFocus.com
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... - Yahoo Finance
BioCardia Reports Q3 2024 Progress and Financials - TipRanks
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - The Manila Times
BioCardia Reports 35% Net Loss Improvement, Advances CardiAMP Trial Milestone | BCDA Stock News - StockTitan
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 - The Manila Times
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Cell therapy weekly: support for commercialization of complex therapies - RegMedNet
BioCardia concludes pivotal heart failure trial - Investing.com
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure - The Manila Times
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.59% - MSN
Beating Heart Patch Market to Make Great Impact in Near Future by 2031 |BIOCARDIA, INC., Athersys, Inc - openPR
Biocardia Inc Azioni (BCDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biocardia Inc Azioni (BCDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Jan 30 '25 |
Buy |
2.38 |
239 |
569 |
107,320 |
| Altman Peter | President and CEO |
Dec 23 '24 |
Buy |
2.06 |
1,000 |
2,060 |
106,581 |
| GILLIS EDWARD M | Senior Vice President, Devices |
Dec 20 '24 |
Sale |
2.00 |
3,257 |
6,514 |
8,968 |
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):